[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nephrotoxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nephrotoxicity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,74,103,126,153,179],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100643948","phase-3-colistin-nephrotoxicity-and-role-of-alpha-lipoic-acid-100643948",false,"NCT07668141","Colistin Nephrotoxicity and Role of Alpha Lipoic Acid","Colistin Nephrotoxicity in Hospitalized Patients: The Role of Biomarkers in Guiding the Preventive Strategies","Inclusion Criteria:\n\n* Adult patients who receive intravenous colistin and had positive cultures of multidrug resistant gram negative bacteria.\n* Patients who receive colistin for at least 3 days during their treatment.\n\nExclusion Criteria:\n\n* Patients who receive inhaled colistin.\n* Patients who had AKI at baseline\n* chronic kidney disease patients on regular hemodialysis.\n* Renal transplant patients\n* Concurrent use of other nephrotoxic drugs e.g. vancomycin, gentamicin, amikacin and amphotericin B.\n* Concurrent use of other antioxidants e.g. vitamin C, vitamin E and N-acetyl cysteine.\n* Patients are not willing to participate in the study.\n* Patients with any missed doses of colistin and or alpha-lipoic acid.\n* Patients with incomplete medical data\n* Pregnant or breastfeeding women.","ALL","18 Years","80 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Nephrotoxicity is a great concern in patients receiving intravenous colistin and there is a disparity in the reported rates between previous studies. Several preclinical researches studied the effect of the antioxidants (e.g. L.carnitine, vitamin C, vitamin E, N-acetyl cysteine, and alpha lipoic acid) in reducing the risk of colistin-induced nephrotoxicity but there is a lack of clinical studies on human. Due to the paucity of studies that early predict colistin-induced nephrotoxicity using early acute kidney injury \"AKI\" biomarkers e.g. kidney injury molecule 1\"KIM1\" and the lack of human studies that evaluate the role of alpha lipoic acid in ameliorating colistin-induced nephrotoxicity, so this study will be conducted.",[27],"Nephrotoxicity",[29,30,31,27],"colistin","Alpa lipoic acid","kidney injury molecule-1","NOT_YET_RECRUITING","2026-06-19",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":21},"2026-06-30",{"date":40,"type":21},"2027-02-28",{"name":42,"class":43},"Helwan University","OTHER",2,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100636345","phase-2-alpha-lipoic-acid-in-mitigating-cisplatin-induced-nephrotoxicity-100636345","NCT07564479","Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity","Evaluation of Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity in Oncology Patients","Inclusion Criteria:\n\n* Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg\u002Fm2 per cycle (21-28 days each or fractionated).\n\nEastern Cooperative Oncology Group (ECOG) performance status 0-2. Baseline serum creatinine within normal range or estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73 m2.\n\nAbility to provide informed consent.\n\nExclusion Criteria:\n\n* Pre existing renal impairment (eGFR \\\u003C 60〖\" mL\u002Fmin\u002F1.73 m\" 〗\\^2or serum creatinine \\> 1.5 × upper limit of normal).\n\nConcomitant use of known nephrotoxic drugs that cannot be stopped (e.g., aminoglycosides, amphotericin B, high dose NSAIDs).\n\nUncontrolled hypertension, decompensated heart failure, or severe hepatic impairment.\n\nKnown allergy or intolerance to ALA. Pregnancy or lactation. Participation in another interventional clinical trial.",{"count":53,"type":21},50,[55],"PHASE2","To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes",[58,27],"Cisplatin Nephrotoxicity",[60,27,61,62],"Cisplatin","ALA","Alpha-Lipoic Acid","RECRUITING","2026-04-26",{"date":66,"type":36},"2026-05-04",{"date":68,"type":36},"2026-03-10",{"date":70,"type":21},"2027-06",{"name":72,"class":43},"Minia University",1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100629574","phase-2-renoprotective-role-of-vitamin-c-and-coenzyme-q10-in-nephrotoxicity-100629574","NCT07476443","Renoprotective Role of Vitamin C and Coenzyme Q10 in Nephrotoxicity","The Potential Renoprotective Effect of Vitamin c and Coenzyme q10 Against Cisplatin Induced Nephrotoxicity in Cancer Patients","VitC-CoQ10","Inclusion Criteria:\n\n* Chemotherapy-naïve patients diagnosed with different types of cancer.\n* Age :adult patients (aged 18-65 years)\n* Candidates eligible for induction chemotherapy (cisplatin+gemcitabine). Baseline (eGFR) ≥60 ml\u002Fmin\u002F1.73 m².\n* Eastern Cooperative Oncology Group (ECOG) performance status \\\u003C2.\n* Hematologic parameters (WBC count ≥ 3,000\u002Fmm³ -- Platelet count ≥ 75,000\u002Fmm³-- Hb level ≥ 8.0 g\u002FdL)\n* Alanine aminotransferase (ALT) ≤3×(ULN).\n\nExclusion Criteria:\n\n* Prior chemotherapy.\n* Uncontrolled Diabetes mellitus, active infection, heart failure, liver impairment, gastritis or G-6-P) deficiency.\n* History of nephrotoxic drugs use over the past 3 months prior to recruitment (e.g., aminoglycosides, amphotericin B, or vancomycin).\n* Known allergy to any of the study drugs.","65 Years",{"count":84,"type":21},75,[55,24],"Cisplatin is a widely used chemotherapy drug for many solid tumors (e.g., lung, bladder, ovarian, head and neck cancers). Despite its efficacy, its clinical use is limited by severe side effects, mainly nephrotoxicity, which occurs in \\~30% of patients after treatment. Once inside cells, cisplatin undergoes activation, leading to DNA and mitochondrial damage, oxidative stress, inflammation, apoptosis, and eventual acute kidney injury (AKI) or chronic kidney disease (CKD). Vitamin C (ascorbic acid) is a water-soluble antioxidant with broad protective roles, including free radical scavenging, DNA and protein protection, and glutathione restoration. Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant involved in mitochondrial energy production and regeneration of other antioxidants (vitamins C \\& E). Both antioxidants are generally safe at studied doses, with only mild gastrointestinal side effects reported. Therefore, evaluating their role in preventing cisplatin-induced nephrotoxicity in cancer patients is clinically valuable.\n\nAim of the study :\n\nThis study aims to evaluate the protective effects of (Vitamin C and Coenzyme q10) against cisplatin-induced nephrotoxicity in chemotherapy-naïve cancer patients.",[27],[60,89,90,91,92,93],"Vitamin C","CoQ10","cancer","nephrotoxicity","KIM-1","2026-03-12",{"date":96,"type":36},"2026-03-17",{"date":98,"type":21},"2026-04-20",{"date":100,"type":21},"2027-08-20",{"name":102,"class":43},"Ain Shams University",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":73},"100601306","phase-2-l-carnitine-protective-effect-in-nephrotoxicity-100601306","NCT07108777","L-Carnitine Protective Effect in Nephrotoxicity","Clinical Study to Evaluate the Possible Protective Effect of L-Carnitine Against Cisplatin-Induced Nephrotoxicity","LC","Inclusion Criteria:\n\n* Male or female patients.\n* Newly diagnosed patients with cancer and with an indication for cisplatin - based chemotherapy.\n* Age between 18 and 75 years.\n* No serious cardiopulmonary comorbidity which could impair involvement in the study.\n* Creatinine clearance value above 50 mL\u002Fmin\u002F1.73 m².\n* Patients who will scheduled to receive at least 3 cycles of cisplatin.\n* Patients with no previous renal diseases (including acute nephropathy, acute and chronic renal failure).\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Metastasis to the central nervous system.\n* Psychiatric disorders.\n* Prior treatment with platinum derivatives.\n* Hypersensitivity to cisplatin, carboplatin or other platinum derivatives.\n* Patients with active infection or any symptoms of sepsis.\n* Acute renal failure or renal surgery within the last 3 months.\n* Patients unfit for cisplatin (patients with impaired renal function, sensorineural hearing loss and cardiomyopathy).\n* Patients with known history or current treatment with nephrotoxic agents.\n* Taking other antioxidant supplements such as Vitamins C and E.","75 Years",{"count":113,"type":21},46,[55],"The goal of this clinical trial is to assess the possible reno-protective effect of L-carnitine against cisplatin-induced nephrotoxicity in patients receiving cisplatin-based chemotherapy. The main question it aims to answer is:\n\nDoes L-carnitine have the ability to protect the kidney against cisplatin-induced nephrotoxicity?",[27],"2025-08-09",{"date":119,"type":36},"2025-08-12",{"date":121,"type":36},"2025-08-10",{"date":123,"type":21},"2026-11-01",{"name":125,"class":43},"Tanta University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":140,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":152},"100322673","phase-2-treatment-of-radiation-and-cisplatin-induced-toxicities-with-tempol-100322673","NCT03480971","Treatment of Radiation and Cisplatin Induced Toxicities with Tempol","A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy","Inclusion Criteria:\n\n1. Be ≥18 years of age with medically diagnosed squamous cell cancer of the head and neck (SCCHN);\n2. Be scheduled to receive radiotherapy or proton therapy administered with a curative intent;\n3. If female and of child bearing potential, be using an effective birth-control method with a history of reliability for the individual participant;\n4. If male and of child bearing potential, adequate methods of contraception must be employed including use of condoms with spermicide. No sperm donation for 90 days until after the conclusion of the study;\n5. Must be receiving cisplatin for chemotherapy;\n6. Be properly informed of the nature and risks of the clinical investigation, comply with all clinical investigation-related procedures, and sign an Informed Consent Form prior to entering the clinical investigation;\n7. Must have a score 2 or less on the ECOG performance status;\n8. Participant life expectancy ≥ 6 months; and\n9. Adequate baseline organ function (hematologic, liver, renal, nutritional and metabolic):\n\nHaematology:\n\nAbsolute neutrophil count (ANC) ≥1.5 Hemoglobin ≥ 10 g\u002FdL Platelets ≥ 100,000 per microliter of blood\n\nHepatic:\n\nTotal bilirubin ≤ 2 X (Upper limit normal) ULN Alanine amino transferase (ALT) and Aspartate aminotransferase (AST) ≤5 x ULN\n\nRenal:\n\nSerum creatinine ≤ ULN or, if \\> ULN calculated creatinine clearance (CrCl) ≥ 60 mL\u002Fmin.\n\nNutritional and metabolic:\n\nUrine Albumin \\\u003C 3.0 mg\u002Fdl\n\nExclusion Criteria:\n\n1. Prior radiotherapy of the head and neck;\n2. Have a clinically significant infection defined as any acute viral, bacterial or fungal infection, which requires specific therapy. Anti-infectious therapy must have been completed within 14 days of starting study treatment;\n3. Be taking any non-approved therapy for oral mucositis, including β-carotene, tocopherol, laser irradiation, brushing the oral mucosa with silver-nitrate prophylactically, systemic TGF-β (transforming growth factor beta), or systemic KGF (keratinocyte growth factor) during or within 14 days of starting treatment;\n4. Be taking mugard;\n5. Be taking prostaglandins, pentoxifylline or leucovorin during or within 14 days of starting treatment;\n6. Be rinsing with allopurinol, hydrogen peroxide, sucralfate, or chlorhexidine mouthwashes during or within 14 days of starting treatment;\n7. Have had a recent, serious, non-malignant medical complication that, in the opinion of the investigator, makes the individual unsuitable for study participation;\n8. Have used an investigational drug within 28 days of the initiation of study treatment;\n9. Have a history of a positive blood test for HIV;\n10. At the time of screening, having a significant active medical illness which, in the opinion of the investigator, would preclude completion of the study;\n11. Participants with a treatment plan consisting of chemoradiation followed by further chemotherapy;\n12. Participants with body weight less than 35 kg, 77 lbs;\n13. Women who are pregnant or who are breastfeeding;\n14. Participants with known intolerance to platin drugs;\n15. History of insulin-dependent Diabetes Mellitus; and\n16. Participants with Hepatitis B\u002FC.",{"count":134,"type":21},120,[55],"A 10 week trial to assess the ability of Tempol to prevent and\u002For reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.",[138,27,139],"Mucositis","Ototoxicity",[141],"cisplatin toxicity","2024-11-18",{"date":144,"type":36},"2024-11-20",{"date":146,"type":36},"2019-05-13",{"date":148,"type":21},"2025-12",{"name":150,"class":151},"Matrix Biomed, Inc.","INDUSTRY",9,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":160,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":177,"locationsCount":73},"100552385","integrated-learning-support-system-based-on-immersive-simulated-training-for-nursing-students-100552385","NCT06472401","Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students","Integrated Learning Support System Based on Immersive Simulated Training for Nursing Students: Randomized Controlled Trial","Inclusion Criteria:\n\n* Be aged ≥ 18 years old;\n* Students enrolled in the last two years of the undergraduate nursing course;\n* Students who have self-declared internet access in their homes to complete the course's online modules.\n\nExclusion Criteria:\n\n* Students who have previous training and\u002For professional experience in the health area;\n* Students who do not complete at least 75% of the workload of the proposed course.",true,{"count":162,"type":21},95,[164],"NA","This study aims to evaluate the effectiveness of an Integrated Learning Support System (ILSS) in preparing undergraduate nursing students for immersive simulated training in managing drug-induced nephrotoxicity. The study hypothesizes that the ILSS, which accommodates different learning styles, will be more effective in reducing stress and anxiety compared to the standard learning model (SLM). The research will involve a parallel randomized controlled trial with 96 students from two Brazilian institutions. The students will be divided into control and experimental groups, with the latter using the ILSS in addition to SLM during preparation. The study will assess outcomes such as knowledge acquisition, skill development, and stress reduction using various instruments, including the Lasater Clinical Judgment Rubric and DASS-21. The study's findings aim to validate the ILSS as a tool to enhance learning outcomes and reduce stress and anxiety, thereby promoting better professional development and patient safety in nursing practice.",[167,168,169,27,170],"Simulation Training","Learning","Educational Technology","Physiological Stress","2024-07-29",{"date":173,"type":36},"2024-07-31",{"date":175,"type":21},"2024-08-01",{"date":148,"type":21},{"name":178,"class":43},"University of Brasilia",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":73},"100527852","kidney-and-blood-pressure-outcomes-in-childhood-cancer-survivors-ccs-100527852","NCT06153147","KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)","KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS): Prospective Study","KINDEST-CCS","Inclusion Criteria:\n\n* 3 years ± 6 months after therapy for first cancer\n* Received high-risk therapy for first cancer, as defined by the Canadian Oncology Group (COG) as alkylating agents; platinums; abdominal or total body radiation; high dose methotrexate; stem cell transplant; nephrectomy; or other therapy which may be known to possibly cause late kidney and\u002For BP effects.\n\nExclusion Criteria:\n\n* Pre-cancer severe CKD and\u002For previous kidney transplant\n* \\>19 years old at 3 years after cancer therapy completion","19 Years",{"count":189,"type":21},500,"OBSERVATIONAL","Background: Childhood cancer survivors (CCS) are at elevated risk of chronic health conditions. Chemotherapies can cause recurrent acute kidney injury which may progress to kidney fibrosis, chronic kidney disease (CKD) or hypertension (HTN). CCS surviving to adulthood are at ≥3 times the risk (vs. non-CCS) for CKD, HTN and lower quality of life. However, the timing of CKD and HTN onset in CCS completing cancer therapy in childhood remains unclear.\n\nGuidelines provide recommendations on managing post-cancer therapy effects in CCS, but they lack specificity on kidney testing content, frequency and complications. This discord is largely due to knowledge gaps on which CCS develop CKD or HTN after cancer therapy, when outcomes occur and their severity. Existing work has shown in select patients, CKD and HTN in CCS likely begins in the first 5 years post-cancer therapy and that the burden is significant. With robust data on CKD and HTN, international CCS follow-up guidelines can be optimized to include detailed and actionable recommendations on kidney and blood pressure monitoring and treatment.",[193,194,195,196,27],"Childhood Cancer","Chronic Kidney Diseases","Hypertension","Acute Kidney Injury","2024-04-15",{"date":199,"type":36},"2024-04-17",{"date":201,"type":36},"2024-01-05",{"date":203,"type":21},"2039-12-31",{"name":205,"class":43},"The Hospital for Sick Children"]